ERJ: 2022 ESC/ERS pulmonary hypertension guidelines incorporate changes and adaptations focusing on clinical management bit.ly/3QtUvb4
ERS publications
16.8K posts
ERS publications
@ERSpublications
European Respiratory Journal, European Respiratory Review, ERJ Open Research, Breathe, the ERS Monograph and ERS Handbooks, and European Lung White Book
- Wheezy infants do not respond to bronchodilators despite evidence of functioning β-adrenoceptors. This is because the predominant aetiology, bronchiolitis, is characterised by small airway oedema and increased mucus, for which β2-agonists are ineffective. bit.ly/2Ws9ffh
- In intubated ARDS patients, prone positioning reduces mortality. On spontaneously breathing patients, oxygenation improved during awake prone positioning. Relevant data on clinical outcomes are expected, especially on #COVID19 patients. bit.ly/2PU3B6v
- Pulmonary thrombosis appears to be common in #COVID19 pneumonia and takes two forms, proximal pulmonary emboli and/or distal thrombosis. The possible mechanisms and clinical implications are discussed. bit.ly/372Xdhw
- Guideline statements for the diagnosis of hypersensitivity pneumonitis have recently been published by the ATS/JRS/ALAT and CHEST. This review examines differences in the two guideline statements and discusses current management options. bit.ly/3o6uJh2
- Evidence-based guidelines for the treatment of sarcoidosis: a major factor in treating patients is the risk of loss of organ function or impairment of quality of life bit.ly/3iAERfY
- Home-based pulmonary rehabilitation is as effective as centre-based in improving exercise capacity and quality of life, and is an option for people with COPD whose access to pulmonary rehabilitation centres is difficult. bit.ly/39HkMm4
- ERJ: Pirfenidone does not significantly reduce the proportion of patients with post-COVID-19 fibrotic changes after 6 months of treatment. FVC % improvement and % HRCT fibrotic reduction with pirfenidone were not statistically different from placebo. bit.ly/4alhGid
- Bronchiectasis, due to its highly heterogenous nature, requires an individualised approach to therapy. Treatment targets symptoms and exacerbations by aiming to improve mucociliary clearance and to reduce airway inflammation and airway infection. bit.ly/3ite4B2
- ERJ: Type 2 airway inflammation in COPD is different than that in severe asthma. There are several very promising therapeutic targets in this pathway to improve health outcomes of patients living with COPD. bit.ly/4a6se3y
- European Respiratory Journal: 1-year DLCO decline was a better indicator of mortality than 1-year FVC decline in patients with >10% emphysema. In non-CPFE IPF patients, 1-year FVC declines >5% and >10% showed comparable mortality associations. bit.ly/48pyqDX
- Long-term e-cigarette exposure may result in pulmonary inflammation and reduced resistance to respiratory infections, which partially reflects the established effects of cigarette exposure, due to a combination of nicotine exposure and oxidative stress. bit.ly/3zwMFE5
- The ERS guidelines for the management of #COVID19 make recommendations in favour of corticosteroids, thromboprophylaxis, anti-IL-6 and noninvasive ventilatory support. These guidelines will be regularly updated as further evidence becomes available. bit.ly/2OlpniF
- Nitrofurantoin is a cause of drug-induced pneumonitis and can result in clinically significant respiratory symptoms manifesting as interstitial lung disease on chest CT, even if the patient has been taking the drug chronically without side-effects bit.ly/3v2m29h
